New survival standards for advanced melanoma


The expectation for survival in patients with advanced melanoma now exceeds 50% at 5 years in patients treated with first-line combination ipilimumab and nivolumab, despite this regimen being associated with substantial toxicity. We discuss the latest updates from the Checkmate-067 study, framing the role of this combination in practice today.

Journal details

Volume 122
Issue number 9
Pages 1275-1276
Available online
Publication date

Crick authors

Crick First author
Crick Corresponding author